Evidence map›Paper›PMID 36285472›Full record

ReviewTechnology in cancer research & treatment

Depicting the Implication of miR-378a in Cancers.

Yuelan Qin, Renba Liang, Pingan Lu, Lin Lai, Xiaodong Zhu

Open access · goldAbstract readReview
In one paragraph

Review in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. [Advances in the role of miR-378a in skeletal muscle development and diseases].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026
    Review
  3. Review
  4. Article
  5. miR-378a-5p targeting BRAF regulates CD4Frontiers in immunology · 2025
    Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Yuelan QinDepartment of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, People's Republic of China.
Renba LiangDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.ORCID 0000-0001-5050-8847
Pingan LuFaculty of Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Lin LaiDepartment of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, People's Republic of China.
Xiaodong ZhuDepartment of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, People's Republic of China.ORCID 0000-0002-7997-8268
Guangxi Medical University · CNAmsterdam University Medical Centers · NLChinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNA-378a (miR-378a), including miR-378a-3p and miR-378a-5p, are encoded in

Indexed as

MicroRNAsNeoplasmsBiomarkersCarcinogenesisCell ProliferationHumansRNA-Binding ProteinsBiomarkersMicroRNAsPPARGC1B protein, humanRNA-Binding Proteinsclinical applicationsinvasionmigrationmiR-378aproliferationtargetstumorigenesis

Identifiers

PMID36285472
PMCPMC9608056
OpenAlexW4307583998

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.